Do you want to read an article? Please log in or register.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Breast Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Breast Cancer
First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
Breast.
Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y
doi: 10.1016/j.breast.2017.06.015.
Breast Cancer
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial
Int J Cancer.
Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L, GIM2 investigators.
doi: 10.1002/ijc.32789.
RECOMMENDED
Breast Cancer
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Lancet Oncol.
Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M
doi: 10.1016/S14702045(18)30750-2.
Breast Cancer
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials
Cancer Treat Rev.
Gyawali B, Niraula S
doi: 10.1016/j.ctrv.2017.08.001.
RECOMMENDED
Breast Cancer
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
doi: 10.1016/S1470-2045(20)30112-1.
Breast Cancer
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
Ann Oncol.
Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Engels K, Nekljudova V, von Minckwitz G, Untch M; investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) study groups.
doi: 10.1093/annonc/mdw610
RECOMMENDED
Breast Cancer
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Lancet.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA, PERSEPHONE Steering Committee and Trial Investigators.
doi: 10.1016/S0140-6736(19)30650-6.
Breast Cancer
Advances in the management of HER2-positive early breast cancer
Crit Rev Oncol Hematol.
Baselga J, Coleman RE, Cortés J, Janni W
doi: 10.1016/